PR PolyResearch

Join Free

NASDAQ

Arbutus Biopharma Corporation (ABUS)

♥ 489 Thanks from members

Arbutus Biopharma Corporation (ABUS) exhibits strong bullish sentiment driven by a landmark Moderna LNP patent settlement, net profitability, a major share repurchase plan, and clinical progress with imdusiran for chronic hepatitis B.

Special Briefing

How to Live for 300 Years: The Longevity Sandbox

Explore plasma cleansing, somatic organ swaps, and BCI.

Other Nasdaq Tickers

GraniteShares 2x Long AAPL Daily ETF (AAPB)

Apple Inc. (AAPL)

Direxion Daily AAPL Bear 1X ETF (AAPD)

Ascentage Pharma Group International - American Depository Shares (AAPG)

Direxion Daily AAPL Bull 2X ETF (AAPU)

Rocket Pharmaceuticals, Inc. - Warrant (RCKTW)